---
title: "Lyra Therapeutics, Inc. (LYRA.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/LYRA.US/overview.md"
symbol: "LYRA.US"
name: "Lyra Therapeutics, Inc."
parent: "https://longbridge.com/zh-CN/quote/LYRA.US.md"
datetime: "2026-04-06T12:39:32.263Z"
locales:
  - [en](https://longbridge.com/en/quote/LYRA.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LYRA.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LYRA.US/overview.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/LYRA.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/LYRA.US/overview.md)


# Lyra Therapeutics, Inc. (LYRA.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | Pharmaceuticals |
| 交易所 | US Market |
| 地址 | 480 Arsenal Way, Watertown, Massachusetts, United States |
| 官网 | [lyratherapeutics.com](https://lyratherapeutics.com) |

## 公司简介

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Carmichael S. Roberts | Co-Founder |
| C. Ann Merrifield | Independent Director |
| Ronan P. O'Brien | Chief Legal Officer |
| Vineeta Belanger | Senior Vice President of Clinical Affairs |
| Allison Nance | Senior Vice President of Regulatory Affairs |
| Elazer R. Edelman | VP of Finance & Risk |
| W. Bradford Smith | Independent Director |
| James R. Tobin | Lead Independent Director |
| Nancy L. Snyderman | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| Maria Palasis | 41.13% | 2026-01-06 |
| Jason Cavalier | 19.45% | 2026-01-06 |
| Sabby Management, LLC | 9.87% | 2025-12-31 |
| North Bridge Venture Partners | 6.64% | 2025-03-18 |
| The Vanguard Group, Inc. | 1.62% | 2025-09-30 |
| Ikarian Capital, LLC | 1.19% | 2025-12-31 |
| DRW Holdings, LLC | 0.95% | 2025-12-31 |
| Nantahala Capital Management, LLC | 0.71% | 2024-09-30 |
| Geode Capital Management, LLC | 0.69% | 2025-12-31 |
| Harlan W. Waksal | 0.61% | 2025-03-18 |

## 业务构成

| 业务线 | 营收 | 占比 |
|---------|---------|-------|
| Developing Targeted Medicines to Address ENT Diseases | 1534000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Lyra Therapeutics, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Developing Targeted Medicines to Address ENT Diseases",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地区分布

| 地区 | 营收 | 占比 |
|--------|---------|-------|
| United States | 1534000 | 100% |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**